A 28% premium on a C$1.88 share price is a modest exit by any standard, which makes Hanmi Pharmaceutical’s decision to fully absorb Aptose Biosciences more revealing than the headline number suggests. The deal closed June 30, with Aptose shareholders receiving C$2.41 per share in cash, common shares set to delist from the TSX around July 3, and the company winding down its public reporting obligations in both Canada and the United States. For Hanmi, this is not a licensing bet hedged with milestones. It is a full ownership play on a clinical-stage asset, tuspetinib, that the Seoul-based company has been quietly building a position around for some time.
The strategic logic rests almost entirely on the TUSCANY trial. Aptose’s lead program pairs tuspetinib, an oral kinase inhibitor, with venetoclax and azacitidine as a frontline triplet therapy in newly diagnosed AML. Data presented at the European Hematology Association Congress in June 2026 showed a composite complete response rate across 29 response-evaluable patients, a dataset still small enough that Hanmi is essentially pricing in a Phase 2 read rather than a near-term commercial story. That willingness to absorb a company at this stage of evidence reflects either a high internal conviction on the mechanism or a calculated move to secure the asset before competitive noise around AML triplet combinations gets louder. Probably both.
Hanmi brings more to this than a checkbook. The company’s existing infrastructure spans oncology, metabolic disease, and immunology, with proprietary drug development platforms and an established record of out-licensing to multinational partners. Tuspetinib fits a broader oncology build-out strategy, and folding in a clinical-stage U.S.-listed company gives Hanmi a cleaner operational footprint in North America than a licensing arrangement would. The amended arrangement agreement, finalized February 23, 2026, and approved by both shareholders and a Canadian court on March 31, suggests the revised terms also took some time to negotiate, which points to genuine complexity in valuing a pre-commercial AML asset.
The number to watch now is the TUSCANY composite complete response rate as enrollment expands beyond those initial 29 evaluable patients. If the signal holds or strengthens at a larger N, Hanmi will have justified this acquisition on clinical grounds alone. If it softens, the deal’s strategic rationale shifts entirely to pipeline optionality, and the premium paid looks harder to defend.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
